ClinVar Miner

Submissions for variant NM_152296.5(ATP1A3):c.2443G>A (p.Glu815Lys) (rs387907281)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000432504 SCV000521282 pathogenic not provided 2018-08-31 criteria provided, single submitter clinical testing The E815K pathogenic variant in the ATP1A3 gene has been reported as a de novo variant in multiple unrelated individuals with alternating hemiplegia of childhood (Heinzen et al., 2012; Rosewich et al., 2012; Ishii et al., 2013). Functional studies indicate E815K significantly reduces enzyme activity compared to the wild-type (Heinzen et al., 2012; Li et al., 2015). This variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The E815K variant is a non-conservative amino acid substitution that occurs at a position that is conserved across species. Missense variants in nearby residues (I810F, I810N, I810S, S811P, E818K) have been reported in the Human Gene Mutation Database in association with ATP1A3-related disorders (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, we interpret E815K as a pathogenic variant.
Invitae RCV000469482 SCV000544728 pathogenic Dystonia 12 2019-12-20 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with lysine at codon 815 of the ATP1A3 protein (p.Glu815Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This variant is a common cause of alternating hemiplegia of childhood. It has been shown to arise de novo in many (>20) affected individuals, and is often associated with a severe phenotype variably including epilepsy, motor function deficits, cognitive impairment and respiratory failure (PMID: 22850527, 23409136, 24631656, 22842232). ClinVar contains an entry for this variant (Variation ID: 37108). Experimental studies have shown that this missense change leads to a reduction in ATP1A3 Na+/K+ ATPase activity (PMID: 25681536). For these reasons, this variant has been classified as Pathogenic.
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV000626997 SCV000747700 pathogenic Global developmental delay; Hemiplegia; Oculogyric crisis 2017-01-01 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000763433 SCV000894199 pathogenic Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome; Dystonia 12; Alternating hemiplegia of childhood 2 2018-10-31 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000432504 SCV001247064 pathogenic not provided 2019-01-01 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV001192636 SCV001360890 pathogenic not specified 2019-10-01 criteria provided, single submitter clinical testing Variant summary: ATP1A3 c.2443G>A (p.Glu815Lys) results in a conservative amino acid change located in the Cation-transporting P-type ATPase, C-terminal domain (IPR006068) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251402 control chromosomes (gnomAD). c.2443G>A has been reported in the literature in multiple individuals affected with alternating hemiplegia of childhood (AHC) (e.g. Heinzen_2012, Ishii_2013, Rosewich_2012). In most of these individuals, this variant was seen as a de novo mutation and was associated with the severe form of the disease. Heinzen et al and Ishii et al suggest that the recurrence of de novo mutation could be due to its location in hypermutable GC-rich sequences of ATP1A3 (Heinzen_2012, Ishii_2013). These data indicate that the variant is very likely to be associated with disease. In functional studies, the variant was found to have reduced Na+/K+ ATPase activity, loss of forward cycling, proton transport and phosphorylation (Heinzen_2012, Li_2015, and Weigand_2014). Four ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics RCV001267254 SCV001445435 pathogenic Inborn genetic diseases 2018-12-14 criteria provided, single submitter clinical testing
Clinical Genetics Karolinska University Hospital,Karolinska University Hospital RCV000432504 SCV001450209 pathogenic not provided 2017-06-28 criteria provided, single submitter clinical testing
OMIM RCV000030750 SCV000053411 pathogenic Alternating hemiplegia of childhood 2 2014-01-01 no assertion criteria provided literature only
GeneReviews RCV000030750 SCV000195716 pathogenic Alternating hemiplegia of childhood 2 2014-05-04 no assertion criteria provided literature only
Biochemical Molecular Genetic Laboratory,King Abdulaziz Medical City RCV000030750 SCV001190829 pathogenic Alternating hemiplegia of childhood 2 2020-02-05 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.